Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Monoclonal antibodies Stories

2014-03-16 16:20:46

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse(TM) (http://dx.doi.org). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this...

2014-03-13 16:28:36

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/4j8x47/global_protein) has announced the addition of the "Global Protein Therapeutics Market Outlook 2018" [http://www.researchandmarkets.com/research/4j8x47/global_protein ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Protein based therapies have found a prominent place in the biopharmaceutical industry since the...

2014-03-13 16:27:58

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" [http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Cancer, one of the leading causes of death worldwide, affected approximately 13 Million...

2014-03-13 08:28:48

MONROVIA, Calif., March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-03-10 16:32:54

BioCentury Conference Presentation to be Webcast SOUTH SAN FRANCISCO, Calif., March 10, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences: -- 26(th) Annual ROTH ConferenceWednesday, March 12, 2014 in Laguna Niguel, California8:00 - 8:30 AM Pacific Time -- BioCentury's Future Leaders in the Biotech Industry ConferenceFriday, March 28, 2014 in New...

2014-03-07 08:21:14

DUBLIN, Mar. 07, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cl5vpz/antibody_target ) has announced the addition of the "Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription" subscription to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 2,400 project entries for...

2014-03-06 23:04:31

Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans. Somerset, NJ (PRWEB) March 06, 2014 Catalent Pharma Solutions, the global...

2014-03-06 16:27:44

SAN DIEGO and MORRIS PLAINS, N.J., March 6, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Immunomedics, Inc. (NASDAQ: IMMU) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between May 9, 2013 and October 9, 2013 (the "Class Period")....

2014-03-06 12:26:44

DUBLIN, Mar. 06, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/njgf7d/research_report ) has announced the addition of the "Concise Analysis of the International and China Monoclonal Antibody Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale of monoclonal antibody was only over...